Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cushing's Disease

Cushing's Disease

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cushing's Disease

10 trials tracked for Cushing's Disease: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 162 citations.

10Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 2 Phase 3 6 Phase 2 1 Other / NA 1
  1. Phase 3 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed · 162 cited
  2. Phase 3 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Completed · 114 cited
  3. Phase 4 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed · 80 cited
  4. Phase 3 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed · 43 cited
  5. Phase 3 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed · 16 cited
  6. Phase 4 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Completed
Show 4 more trials
  1. Phase 3 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed
  2. Phase 3 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed
  3. Phase 2 Safety and Efficacy of LCI699 in Cushing's Disease Patients Completed
  4. N/A Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomas
Oncology Meta-analysis
Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomas Surgery Technique Shows High Success for Pituitary Tumor Treatment
This meta-analysis of 493 patients with functioning pituitary adenomas found that medial cavernous sinus wall resection (MCSWR) is associate…
A surgical technique called MCSWR shows high rates of hormone remission and tumor removal for patients with specific pituitary gland tumors.
Sep 18, 2026
Transsphenoidal surgery achieves 73.88% remission rate in Cushing's Disease
Oncology Meta-analysis
Transsphenoidal surgery achieves 73.88% remission rate in Cushing's Disease Factors linked to higher remission rates in Cushing's Disease surgery
A meta-analysis of 11,666 patients with Cushing's Disease found that transsphenoidal surgery yields an overall remission rate of 73.88%. Hig…
New data identifies specific surgical and imaging factors that may help doctors predict better outcomes for patients undergoing surgery for …
Jul 26, 2026